Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
SKB264-II-06
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
- NCT05642780 ↗
- Active, not recruiting
- Klus Pharma Inc.
- Focused
We haven't built an HCP commentary report on SKB264-II-06 (SKB264 and pembrolizumab) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SKB264-II-06 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 8 |
The trial
ClinicalTrials.gov- Official title
- A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Solid Tumor
- Interventions
- SKB264; Pembrolizumab
- Arms
- cohort A · Experimental
- cohort B · Experimental
- cohort C · Experimental
- cohort D · Experimental
- Cohort E · Experimental
- Enrollment
- 240 (estimated)
- Primary outcomes
- Dose limiting toxicity (DLT) and adverse events (AEs)
- Objective Response Rate (ORR)
- Prostate-specific antigen (PSA) response rate (Cohort D)
- Sponsor
- Klus Pharma Inc. with Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc., Clario
- Start
- Jan 17, 2023
- Primary completion
- Nov 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05642780 · updated Oct 14, 2025